Evidence map›Paper›PMID 31888969›Full record

ArticleNeurology2020

White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.

Anja Soldan, Corinne Pettigrew, Yuxin Zhu, Mei-Cheng Wang, Abhay Moghekar, Rebecca F Gottesman, Baljeet Singh, Oliver Martinez, Evan Fletcher, Charles DeCarli and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.

  1. Systematic review ofFrontiers in aging neuroscience · 2023
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cerebrovascular markers of WMH and infarcts in ADNI: A historical perspective and future directions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. White matter hyperintensity longitudinal morphometric analysis in association with Alzheimer disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Anja SoldanFrom the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis. asoldan1@jhmi.edu.ORCID 0000-0002-6193-0418
Corinne PettigrewFrom the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.ORCID 0000-0003-4264-275X
Yuxin ZhuFrom the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.
Mei-Cheng WangFrom the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.
Abhay MoghekarFrom the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.ORCID 0000-0001-9464-1551
Rebecca F GottesmanFrom the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.
Baljeet SinghFrom the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.
Oliver MartinezFrom the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.
Evan FletcherFrom the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.
Charles DeCarliFrom the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.
Marilyn AlbertFrom the Department of Neurology (A.S., C.P., A.M., R.F.G., M.A.), The Johns Hopkins University School of Medicine; Department of Biostatistics (Y.Z., M.-C.W.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Department of Neurology (B.S., O.M., E.F., C.D.), School of Medicine, University of California, Davis.
BIOCARD Research Team
Johns Hopkins University · US

Funding

Project 2 MeasurementU19AG033655 · NIA · JOHNS HOPKINS UNIVERSITY · PI Abhay Moghekar · 2014 to 2026
$51.5M
'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI HUGANIR, RICHARD L · 1985 to 2019
$37.6M
Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI Corinne Pettigrew · 2020 to 2026
$29.3M
NIA NIH HHS P30 AG066507NIA NIH HHS P50 AG005146NIA NIH HHS U19 AG033655
6 · The paper itself

Abstract

objectiveRecent studies suggest that white matter hyperintensities (WMH) on MRI, which primarily reflect small vessel cerebrovascular disease, may play a role in the evolution of Alzheimer disease (AD). In a longitudinal study, we investigated whether WMH promote the progression of AD pathology, or alter the association between AD pathology and risk of progression from normal cognition to mild cognitive impairment (MCI).

methodsTwo sets of analyses were conducted. The relationship between whole brain WMH load, based on fluid-attenuated inversion recovery MRI, obtained in initially cognitively normal participants (n = 274) and time to onset of symptoms of MCI (n = 60) was examined using Cox regression models. In a subset of the participants with both MRI and CSF data (n = 204), the interaction of WMH load and CSF AD biomarkers was also evaluated.

resultsBaseline WMH load interacted with CSF total tau (t-tau) with respect to symptom onset, but not with CSF β-amyloid 1-42 or phosphorylated tau (p-tau) 181. WMH volume was associated with time to symptom onset of MCI among individuals with low t-tau (hazard ratio [HR] 1.35, confidence interval [CI] 1.06-1.73,

conclusionThese results suggest that WMH primarily affect the risk of progression when CSF measures of neurodegeneration or neuronal injury (as reflected by t-tau) are low. However, CSF biomarkers of amyloid and p-tau and WMH appear to have largely independent and nonsynergistic effects on the risk of progression to MCI.

Indexed as

AdultAgedAged, 80 and overAge of OnsetAlzheimer DiseaseAmyloid beta-PeptidesBiomarkersBrainCognitive DysfunctionDisease ProgressionFemaleHumansLongitudinal StudiesMagnetic Resonance ImagingMaleMiddle AgedAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersPeptide Fragmentstau Proteins

Identifiers

PMID31888969
PMCPMC7238945
OpenAlexW2998727031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.